Artificial Intelligence In Genomics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 3.1 billion
Estimated Base Value
2035 Forecast
US$ 18.0 billion
Projected Market Value
CAGR 2026–2035
19.2%
Compound Annual Growth
Largest Segment
In the full report
Fastest Growing Segment
In the full report
Leading Region
North America
Fastest Growing Region
In the full report
Top Country
In the full report
By Market Share
Largest market
Key Players
Tempus Labs
Emerging Players
Insilico Medicine, Valo Health
Indicative preview. The market size, forecast and CAGR are our published estimates. The segments, regions, countries and companies on this page show the report's scope; their sizes, shares and growth rates are researched and modelled when the full report is prepared. How our figures are built
Artificial Intelligence In Genomics Market Overview
The Artificial Intelligence in Genomics market involves the application of AI and machine learning algorithms to analyze genomic datasets, primarily within the pharmaceutical industry. This market provides solutions that enhance target identification, lead optimization, biomarker discovery, patient stratification, and adverse drug reaction prediction. Key buyers include pharmaceutical and biotechnology companies, academic and research institutions, and clinical laboratories, all seeking to improve therapeutic efficacy, optimize clinical trial design, and personalize treatments through advanced genomic analysis.
The Artificial Intelligence in Genomics market is estimated at $3.1 Bn in 2025 and is forecast to reach $18.0 Bn in 2035, growing at a CAGR of 19.2% from 2025 to 2035. This growth is driven by the surge in genomic data generation and the need for accelerated drug discovery and development processes. Advances in AI algorithms and computational power also contribute to demand. However, data privacy and security concerns, high computational costs, and a lack of standardized genomic data present restraints to market expansion.
The market is segmented by Type (AI Software Platforms, AI Services, AI Solutions), Technology (Machine Learning, Deep Learning, Natural Language Processing), Application (Drug Discovery & Development, Precision Medicine, Disease Diagnosis & Prognosis), End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions), Deployment (Cloud-Based, On-Premise), and Component (Algorithms & Models, Data Integration & Management Tools). Geographically, the market is served across Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. Leading companies include Tempus Labs, Insitro, Recursion Pharmaceuticals, and Sophia Genetics. The full report covers market trends, drivers, restraints, and opportunities, providing a comprehensive analysis of the Artificial Intelligence in Genomics market.
Market Definition & Overview
The Artificial Intelligence in Genomics Market within the pharmaceutical industry encompasses the application of AI and machine learning algorithms to analyze, interpret, and leverage vast genomic datasets for accelerating drug discovery, development, and personalized medicine. This market focuses on solutions that enhance target identification, lead optimization, biomarker discovery, patient stratification, and adverse drug reaction prediction by processing DNA, RNA, and proteomic information at scale. It aims to improve therapeutic efficacy, optimize clinical trial design, and personalize treatments, ultimately transforming pharmaceutical research and development pipelines and clinical practice.
Scope
- Global market coverage across all major regions
- Analysis by AI technology (e.g., machine learning, deep learning) and genomic application
- Coverage of solutions primarily used by pharmaceutical companies and biotechnology firms
- Historical data and future forecasts spanning typical study periods
Inclusions
- AI-powered software platforms for genomic data analysis and interpretation
- Machine learning algorithms specifically for genetic variant interpretation
- AI tools for drug target identification and validation using genomic data
- AI solutions for precision oncology and pharmacogenomics applications
- Services for AI-driven biomarker discovery and development
- Integration of AI with next-generation sequencing data analysis
Exclusions
- General AI applications not specifically focused on genomics
- Genomic sequencing services without AI integration or analysis
- AI applications in other non-genomic pharmaceutical areas like clinical operations
- Traditional bioinformatics tools lacking advanced AI capabilities
- AI in genomics for non-pharmaceutical sectors like agriculture or consumer genetics
Market Size Forecast
Executive Summary
- The Artificial Intelligence In Genomics market is valued at $3.1 Bn in 2025 and is forecast to reach $18.0 Bn by 2035, reflecting a robust CAGR of 19.2% as demand accelerates across every major segment and region over the ten-year outlook.
- North America leads the market today.
- Strategic alliances and targeted M&A are rapidly reshaping the competitive landscape, with major pharmaceutical companies acquiring AI genomic startups to integrate advanced drug discovery platforms and accelerate therapeutic development pipelines for precision medicine.
- The convergence of declining sequencing costs and advanced AI algorithms is a primary catalyst, propelling the market towards widespread adoption in clinical diagnostics and personalized oncology, profoundly transforming patient stratification and treatment efficacy.
- Breakthroughs in deep learning for genomic variant interpretation and multi-omics integration are pivotal, unlocking unprecedented efficiencies in target identification and lead optimization, significantly compressing drug development timelines across therapeutic areas.
- Evolving regulatory frameworks for AI-driven diagnostics and data governance will critically influence market expansion, demanding robust validation protocols and ethical data-sharing models to foster trust and accelerate clinical integration.
- North America and Europe currently dominate investment and innovation, yet emerging Asian markets with vast, diverse genomic datasets represent significant untapped potential, poised for rapid growth as infrastructure and expertise mature.
- Talent scarcity in bioinformatics and AI engineering remains a critical bottleneck, necessitating strategic investments in workforce development and academic partnerships to sustain innovation and scale market-wide adoption effectively.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Valuation
The Artificial Intelligence in Genomics Market was valued at $3.1 billion in the base year.
Future Market Projection
The market is projected to reach $18.0 billion by the forecast year, indicating substantial expansion.
Robust Growth Outlook
This significant market expansion is driven by an impressive Compound Annual Growth Rate (CAGR) of 19.2%.
Drug Discovery Dominance
The drug discovery and development segment is expected to remain a leading application, leveraging AI for accelerated therapeutic innovation.
Precision Medicine Trend
A notable trend is the increasing adoption of AI for precision medicine, enabling tailored treatments based on individual genetic profiles.
Regional Leadership
North America is anticipated to maintain its leadership position, driven by extensive R&D investments and advanced technological infrastructure.
Market Dynamics
Market Trends
- Increased adoption of AI for genomic data analysis in drug discovery.
- Growing use of machine learning in personalized medicine workflows.
- Integration of multi-omics data with AI for comprehensive insights.
- Rising focus on ethical AI and data privacy in genomic research.
Growth Drivers
- Surge in genomic data generation fuels demand for AI tools.
- Need for accelerated drug discovery and development processes.
- Advances in AI algorithms and computational power.
- Increasing investment from pharmaceutical companies in AI genomics.
Restraints
- Data privacy and security concerns remain a significant hurdle.
- High computational costs limit accessibility for smaller entities.
- Lack of standardized genomic data hinders AI model development.
- Regulatory complexities and ethical considerations pose challenges.
Opportunities
- Development of novel AI solutions for rare disease diagnosis.
- Expansion into pharmacogenomics for tailored drug prescriptions.
- Creating AI platforms for predictive analytics in disease prevention.
- Partnerships between tech firms and genomic research institutions.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | AI Software PlatformsAI ServicesAI Solutions |
| By Technology | Machine LearningDeep LearningNatural Language ProcessingComputer VisionPredictive AnalyticsReinforcement LearningGenerative AI |
| By Application | Drug Discovery & DevelopmentPrecision MedicineDisease Diagnosis & PrognosisBiomarker DiscoveryGenomic Sequencing & AnnotationVariant PrioritizationClinical TrialsPersonalized Therapeutics |
| By End-User | Pharmaceutical & Biotechnology CompaniesAcademic & Research InstitutionsClinical LaboratoriesHospitals & Healthcare ProvidersContract Research OrganizationsGovernment Agencies |
| By Deployment | Cloud-BasedOn-PremiseHybrid |
| By Component | Algorithms & ModelsData Integration & Management ToolsGenomic Databases & Knowledge BasesCloud & Computing InfrastructureVisualization & Reporting ToolsApplication Programming Interfaces & Software Development Kits |
Regional Analysis
- North America leads the AI in genomics market due to its robust R&D infrastructure, substantial venture capital investments, and the presence of key pharmaceutical and biotechnology firms. Extensive government funding and advanced healthcare systems further drive innovation and adoption in this region.
- The Asia Pacific region is rapidly expanding in AI genomics, driven by burgeoning healthcare expenditure, massive patient populations for genomic data, and supportive government policies. Increasing awareness and investment in precision medicine further accelerate its growth across key countries.
- Europe exhibits a noteworthy trend towards collaborative, cross-border genomics projects, leveraging AI for shared data analysis while navigating stringent data privacy regulations (GDPR). This fosters innovation in personalized medicine through multi-national research initiatives.
| North America | Latin America | Europe | Asia Pacific | Middle East & Africa |
North America
- Leading in AI innovation and genomic research, North America benefits from strong venture capital funding, a robust pharmaceutical industry, and numerous academic-industrial collaborations, fostering rapid technological advancements.
Latin America
- Exhibiting growing interest and investment in genomic medicine and AI, particularly in larger economies like Brazil and Mexico, this region focuses on precision medicine initiatives and addressing regional health challenges.
Europe
- The European market benefits from strong public and private funding for life sciences, established research infrastructures, and collaborative initiatives like national genomic projects, though regulatory landscapes can vary across countries.
Asia Pacific
- This region is driven by significant government investment in genomic research and AI development, large patient populations for data generation, and a rising number of domestic biotech companies, particularly in China and India.
Middle East & Africa
- This region is emerging as a market due to increasing healthcare infrastructure investments, national genomics programs (e.g., UAE, Saudi Arabia), and a rising demand for advanced diagnostic and therapeutic solutions, often through international partnerships.
Country Analysis
Market size, share and growth for each country are in the full report. Growth across countries is shaped by local regulatory, infrastructure and demand-side factors specific to each geography.
| Region | Countries covered |
|---|---|
| North America | United States, Canada, Mexico |
| Latin America | Brazil, Argentina |
| Europe | Germany, United Kingdom, Spain, Russia, France, Switzerland, Italy |
| Asia Pacific | China, Japan, Malaysia, India, South Korea, Australia, Taiwan, Singapore |
| Middle East & Africa | United Arab Emirates, South Africa, Saudi Arabia, Israel |
Countries Covered (24)
United States, Canada, Mexico, Brazil, Argentina, Germany, United Kingdom, Spain, Russia, France, Switzerland, Italy, China, Japan, Malaysia, India, South Korea, Australia, Taiwan, Singapore, United Arab Emirates, South Africa, Saudi Arabia, Israel
Competitive Landscape
| Key companies | Key Strategy | Key Products |
|---|---|---|
Insitro | To industrialize drug discovery and development by combining machine learning, human genetics, and functional genomics. | Insitro Human PlatformiPSC-derived cellular modelsMachine learning-driven target discovery |
Oxford Nanopore Technologies | To enable the analysis of anything, by anyone, anywhere, through real-time, high-performance, and accessible nanopore sequencing. | MinIONGridIONPromethION+1 |
Recursion Pharmaceuticals | To decode biology by industrializing drug discovery through a massive-scale, automated, AI-driven experimental platform. | Recursion Operating SystemPhenomics platformTarget discovery programs |
Sophia Genetics | To democratize data-driven medicine worldwide by providing AI-powered analysis of genomic and radiomic data to healthcare institutions. | SOPHiA DDM PlatformAI-powered diagnostic solutionsData-driven medicine analytics |
Tempus Labs | To build the world's largest library of clinical and molecular data and an operating system to make that data accessible and useful for physicians and researchers. | Tempus xTTempus xFTempus xG+1 |
Companies Profiled (20)
Tempus Labs, Insitro, Recursion Pharmaceuticals, Sophia Genetics, Oxford Nanopore Technologies, BenevolentAI, Freenome, Guardant Health, Deep Genomics, Exscientia, DNAnexus, Owkin, Genesis Therapeutics, Atomwise, Personalis, Natera, Bionano Genomics, Emedgene, Lifebit Biotech, Verge Genomics
The global Artificial Intelligence In Genomics market features a competitive landscape led by Tempus Labs, Insitro, Recursion Pharmaceuticals, Sophia Genetics, Oxford Nanopore Technologies, and BenevolentAI, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
Tempus Labs
Insitro
Recursion Pharmaceuticals
Sophia Genetics
Oxford Nanopore Technologies
BenevolentAI
Freenome
Guardant Health
Deep Genomics
Exscientia
DNAnexus
Owkin
Genesis Therapeutics
Atomwise
Personalis
Natera
Bionano Genomics
Emedgene
Lifebit Biotech
Verge Genomics
* Market shares and positioning of each company are in the full report.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Pfizer Forges Strategic Alliance with GenomAI for Precision Oncology
Pfizer announced a multi-year partnership with GenomAI, an AI genomics leader, to leverage GenomAI's platform for identifying novel therapeutic targets and biomarkers in oncology, accelerating precision medicine drug discovery.
DeepGenetics Unveils AI-Powered Genomic Variant Interpretation System
DeepGenetics launched 'VarAI Pro', a groundbreaking AI platform designed to rapidly analyze complex genomic variants, significantly improving the speed and accuracy of disease diagnostics and treatment stratification in clinical trials.
GenomeInsight Secures Series C to Scale AI Drug Discovery
GenomeInsight, a startup specializing in AI-driven genomic analysis for drug development, successfully closed Series C funding round to expand its research capabilities and global commercialization efforts.
Roche Acquires AI Genomics Pioneer HelixSense for Enhanced R&D
Pharmaceutical giant Roche announced the acquisition of HelixSense, a leading AI genomics company focused on computational drug design, aiming to integrate HelixSense's predictive AI models into its early-stage drug discovery pipelines.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $3.1 Bn |
| Market Size (Forecast) | $18.0 Bn |
| CAGR | 19.2% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 24 Countries |
| Segments Covered | 6 Segments, 33 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the Artificial Intelligence In Genomics Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$6,000 single user · US$8,000 enterprise per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$6,000 single user · US$8,000 enterprise per market · bought online, prepared after your order and emailed to you
See what is inside →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
VP, Corporate Strategy
Industrial manufacturing company
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Director, Investment Research
Private equity firm
“We now use these reports in every planning cycle. The regional granularity, and the same numbers across the report, the dashboard and the Excel, save our team real time.”
Head of Market Intelligence
Specialty chemicals company
Frequently Asked Questions
Common questions about this report and our research
The Artificial Intelligence In Genomics market is estimated at $3.1 Bn in 2025.
The Artificial Intelligence In Genomics market is forecast to reach $18.0 Bn in 2035, exhibiting a CAGR of 19.2% from 2025 to 2035.
The main segments include Type (AI Software Platforms, AI Services), Technology (Machine Learning, Deep Learning), Application (Drug Discovery & Development, Precision Medicine), End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions), Deployment (Cloud-Based, On-Premise), and Component (Algorithms & Models, Data Integration & Management Tools).
Leading companies in this market include Tempus Labs, Insitro, Recursion Pharmaceuticals, Sophia Genetics, Oxford Nanopore Technologies, BenevolentAI, Freenome, Guardant Health, Deep Genomics, Exscientia, DNAnexus, and Owkin.
The report provides a comprehensive analysis of the Artificial Intelligence In Genomics market, covering market trends, growth drivers, and restraints. It also details market segmentation by type, technology, application, end-user, deployment, and component, across key regions.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the interactive dashboard with Excel download, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Prepared and quality-checked by our analysts after your order; our research team will get back to you with the timelines.
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
AI Biomanufacturing Intelligence Market
$684.0 Mn in 2025 · 25.1% CAGR
AI Clinical Genomics Market
$2.7 Bn in 2025 · 18.7% CAGR
AI for Genomics Research Market
$1.9 Bn in 2025 · 18.3% CAGR
Biotech Manufacturing Intelligence Market
$1.2 Bn in 2025 · 15.1% CAGR
Cancer Genomics Market
$18.9 Bn in 2025 · 12.1% CAGR
Clinical Genomics Market
$15.6 Bn in 2025 · 11.3% CAGR
Consumer Genomics Market
$2.1 Bn in 2025 · 21.6% CAGR
Single Cell Genomics Market
$4.8 Bn in 2025 · 15.7% CAGR
Analysis on Pharmaceuticals
- Market InsightsAI in Healthcare: From Medical Scribes to Protein Design, 12 Markets Sized
Healthcare AI is splitting into dozens of specialised markets. Our estimates show documentation and diagnostics growing fastest.
- Market InsightsPharma Robots Market to 2035: Precision Drives Automation
Pharma robots are moving deeper into pharmaceutical workflows as buyers seek precision, contamination control, and flexible automation across labs and plants.
More Pharmaceuticals research: all Pharmaceuticals market reports · all Viewpoints · Market Insights